Virtual Education Program for Atrial Fibrillation
Trial Summary
What is the purpose of this trial?
The goal of this study is to determine the effectiveness of a direct-to-provider virtual education program ("AF and EKG Interpretation Project ECHO") for primary care providers who manage patients with atrial fibrillation (AF). The main questions this study aims to answer are: 1. Will participants have improvement in knowledge and confidence in managing patients with atrial fibrillation after program completion? 2. Will quality and performance metrics improve at the patient level for program participants? Participants will be asked to: * Participate in 12 hours of virtual education sessions over twelve weeks via Zoom. * Complete a knowledge and confidence assessment online before the program starts and after its completion.
Research Team
Anil Gehi, MD
Principal Investigator
University of North Carolina, Chapel Hill
Eligibility Criteria
This trial is for primary care providers (Physicians, Nurse Practitioners, Physician Assistants) who are based in North Carolina and manage adult patients with atrial fibrillation. There are no specific exclusion criteria mentioned, so it appears open to all eligible healthcare professionals within the state.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- AF and EKG Interpretation Project ECHO
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of North Carolina, Chapel Hill
Lead Sponsor
Wake Forest University
Collaborator
Duke University
Collaborator
Bristol-Myers Squibb
Industry Sponsor
Christopher Boerner
Bristol-Myers Squibb
Chief Executive Officer since 2023
PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis
Deepak L. Bhatt
Bristol-Myers Squibb
Chief Medical Officer since 2024
MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania